Effective Management of Pregnancy- and Lactation-Associated Osteoporosis Using Romosozumab: A Clinical Case Report

Pregnancy- and lactation-related osteoporosis (PLO) is a rare characterized by reduced bone density and increased fracture risk during late pregnancy or early postpartum. Because of its rarity, no well-established treatment exists for PLO. Here, we report a case demonstrating significant improvements in bone density and the absence of new fractures after 12 mo of romosozumab (ROMO) treatment following weaning. This report suggests that ROMO could effectively increase bone density and reduce fracture risk in patients with PLO.